DOI QR코드

DOI QR Code

Years of Potential Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Iran

  • Khorasani, Soheila (Department of Health Economics and Management, School of Public Health, Tehran University of Medical Sciences) ;
  • Rezaei, Satar (School of Public Health, Kermanshah University of Medical Sciences) ;
  • Rashidian, Hamideh (Biostatistics and Epidemiology Department, Kerman University of Medical Sciences) ;
  • Daroudi, Rajabali (Department of Health Economics and Management, School of Public Health, Tehran University of Medical Sciences)
  • Published : 2015.03.18

Abstract

Background: Cancer is recently one of the major concerns of the public health both in the world and Iran. To inform priorities for cancer control, this study estimated years of potential life lost (YPLL) and productivity losses due to cancer-related premature mortality in Iran in 2012. Materials and Methods: The number of cancer deaths by sex for all cancers and the ten leading causes of cancer deaths in Iran in 2012 were obtained from the GLOBOCAN database. The life expectancy method and the human capital approach were used to estimate the YPLL and the value of productivity lost due to cancer-related premature mortality. Results: There were 53,350 cancer-related deaths in Iran. We estimated that these cancer deaths resulted in 1,112,680 YPLL in total, 563,332 (50.6%) in males and 549,348 (49.4%) in females. The top 10 ranked cancers accounted for 75% of total death and 70% of total YPLL in the males and 69% for both death and YPLL in the females. The largest contributors for YPLL in the two genders were stomach and breast cancers, respectively. The total cost of lost productivity due to cancer-related premature mortality discounted at 3% rate in Iran, was US$ 1.93 billion. The most costly cancer for the males was stomach, while for the females it was breast cancer. The percentage of the total costs that were attributable to the top 10 cancers was 67% in the males and 71% in the females. Conclusions: The YPLL and productivity losses due to cancer-related premature mortality are substantial in Iran. Setting resource allocation priorities to cancers that occur in younger working-age individuals (such as brain and central nervous system) and/or cancers with high incidence and mortality rates (such as stomach and breast) could potentially decrease the productivity losses and the YPLL to a great extent in Iran.

Keywords

Years of potential life lost;productivity costs;cancer;economic burden;Iran

References

  1. Yabroff KR, Bradley CJ, Mariotto AB, et al (2008). Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst, 100, 1755-62. https://doi.org/10.1093/jnci/djn383
  2. Abachizadeh K, Mohagheghi M-A, Mosavi-Jarrahi A (2011). Setting research priorities to reduce burden of cancer in Iran: an institutional experience. Asian Pac J Cancer Prev, 12, 2365-70.
  3. Akbarzadeh Ba, Esmaeili M, Kimiafar K (2008). Medical information management and assessment of direct costs of treatment of lung cancer. Health Information Management, 5, 151-8 (in Persian).
  4. Bazyar M, Pourreza A, Harirchi I, et al (2010). Medical and non-medical direct costs of cancers in patients hospitalized in Imam Khomeini Cancer Institution-2010. Hospital, 11, 39-50 (in Persian).
  5. Bradley CJ, Yabroff KR, Dahman B, et al (2008). Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst, 100, 1763-70. https://doi.org/10.1093/jnci/djn384
  6. Burnet N, Jefferies S, Benson R, et al (2005). Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer, 92, 241-5.
  7. D'Souza ND, Murthy NS, Aras RY (2013). Projection of cancer incident cases for India -till 2026. Asian Pac J Cancer Prev, 14, 4379-86. https://doi.org/10.7314/APJCP.2013.14.7.4379
  8. Davari M, Yazdanpanah F, Aslani A, et al (2013). The direct medical costs of breast cancer in Iran: analyzing the patient's level data from a cancer specific hospital in Isfahan. Int J Prev Med, 4, 748.
  9. Ekwueme DU, Chesson HW, Zhang KB, et al (2008). Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis- United States, 2003. Cancer, 113, 2936-45. https://doi.org/10.1002/cncr.23761
  10. Ekwueme DU, Guy Jr GP, Li C, et al (2011). The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol, 65, 133-43
  11. Ferlay J, Soerjomataram I, Ervik M, et al (2012). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 10/10/2014. [Online].
  12. Gardner JW, Sanborn JS (1990). Years of potential life lost (YPLL)-what does it measure? Epidemiol, 1, 322-9. https://doi.org/10.1097/00001648-199007000-00012
  13. Hanly P, Pearce A, Sharp L (2014). The cost of premature cancerrelated mortality: a review and assessment of the evidence. Expert review of pharmacoeconomics and outcomes research, 1-23.
  14. Hanly P, Soerjomataram I, Sharp L (2015). Measuring the societal burden of cancer: The cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer, 136, 136-45. https://doi.org/10.1002/ijc.29105
  15. Hanly P, Timmons A, Walsh PM, et al (2012). Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health, 15, 429-36. https://doi.org/10.1016/j.jval.2011.12.012
  16. Hanly PA, Sharp L (2014). The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer, 14, 224. https://doi.org/10.1186/1471-2407-14-224
  17. Horm JW, Sondik EJ (1989). Person-years of life lost due to cancer in the United States, 1970 and 1984. Am J Public Health, 79, 1490-3. https://doi.org/10.2105/AJPH.79.11.1490
  18. Iran SCo (2013). Iran Statistical Yearbook, available from: http://www.amar.org.ir/Default.aspx?tabid=2153, accessed on:(10.09.2013) [Online].
  19. Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907. https://doi.org/10.1158/1055-9965.EPI-10-0437
  20. Jonsson B, Wilking N (2007). The burden and cost of cancer. Ann Oncol, 18, 8-22.
  21. Kanavos P (2006). The rising burden of cancer in the developing world. Ann oncol, 17, 15-23.
  22. Kim JL, Cho KH, Park EC, et al (2014). A single measure of cancer burden combining incidence with mortality rates for worldwide application. Asian Pac J Cancer Prev, 15, 433-9. https://doi.org/10.7314/APJCP.2014.15.1.433
  23. Lee WC (1997). Quantifying the future impact of disease on society: life table-based measures of potential life lost. Am J Public Health, 87, 1456-60. https://doi.org/10.2105/AJPH.87.9.1456
  24. Li C, Ekwueme DU (2010). Years of potential life lost caused by prostate cancer deaths in the United States-projection from 2004 through 2050. Cancer Epidemiol, 34, 368-72. https://doi.org/10.1016/j.canep.2010.04.015
  25. Ministry of Labour and Social Welfare, Iran (2013). Labour Market Information System. available from: http://www.Amarkar.Ir/asp/statreport.Aspx. accessed on:(01/04/2013) [Online].
  26. Naghavi M, Abolhassani F, Pourmalek F, et al (2009). The burden of disease and injury in Iran 2003. Population Health Metrics, 7, 9. https://doi.org/10.1186/1478-7954-7-9
  27. Pham TM, Fujino Y, Matsuda S, et al (2010). Premature mortality due to cancer in Japan, 1995 and 2005. Int J Cancer, 127, 190-4. https://doi.org/10.1002/ijc.25021
  28. Rashidian H, Davoudi R, Ghiasvand R, et al (2013). Prevalence and Incidence of premenopausal and postmenopausal breast cancer in Iran in 2010. Basic Clinical Cancer Res, 5, 2-10.
  29. Roya N, Abbas B (2013). Colorectal cancer trends in Kerman province, the largest province in Iran, with forecasting until 2016. Asian Pac J Cancer Prev, 14, 791-3. https://doi.org/10.7314/APJCP.2013.14.2.791
  30. Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70. https://doi.org/10.7314/APJCP.2012.13.1.367
  31. Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased trend of breast cancer mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70. https://doi.org/10.7314/APJCP.2012.13.1.367
  32. The central bank of Iran (CBI). 2014. exchange rate, available at: Http://www.Cbi.Ir/exrates/rates_fa.Aspx, accessed on: (20.09.2014) [Online].
  33. World Bank (2014). World Development Indicators, Labor force participation rate, available at: http://data.worldbank.org/indicator/SL.TLF.CACT.ZS ,accessed on:(10.10.2014).
  34. World Health Organization. 2014. Global Health Observatory Data Repository ; available from: http://apps.who.int/gho/data/?theme=mainandvid=60760, accessed on:(01/10/2014) [Online].

Cited by

  1. Burden of Cancers Related to Smoking among the Indonesian Population: Premature Mortality Costs and Years of Potential Life Lost vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6903
  2. Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention vol.63, pp.7, 2018, https://doi.org/10.1038/s10038-018-0450-y